Global R&D Pipeline
My Favorite
Hot Targets:
IL4R
Back
Total number of drugs
96
Phase II and later clinical stages
13.5%
Involving companies
133
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stapokibart | Stapokibart | Monoclonal antibody | Immune System Diseases Infectious Diseases Congenital Disorders Otorhinolaryngologic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Eye Diseases Other Diseases | IL-4Rα inhibitors | Keymed Biomedical Technology (Chengdu) Co., Ltd. | CSPC Pharmaceutical Group Ltd. Keymed Biomedical Technology (Chengdu) Co., Ltd. Chengdu Kangnuoxing Biopharma,Inc. Keymed Biosciences, Inc. | Approved | Approved | China | 2024-09-10 | 2024-09-10 | Breakthrough Therapy（China） Priority Review（China） | - | - | - | - | Stapokibart | - | - | detail > | |
| IL-4-Y | IL-4-Y | Synthetic peptide | Skin and Musculoskeletal Diseases | IL-4Rα modulators | University of Warsaw | University of Warsaw | Preclinical | - | - | - | - | - | - | - | - | - | IL-4-Y | - | - | detail > | |
| IL-4Ra (Scinai) | IL-4Ra (Scinai) | Monoclonal antibody | Immune System Diseases Congenital Disorders Respiratory Diseases Skin and Musculoskeletal Diseases | IL-4Rα inhibitors | Scinai Immunotherapeutics Ltd. | Scinai Immunotherapeutics Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | IL-4Ra (Scinai) | - | - | detail > | |
| IL4R(Qubit Pharmaceuticals) | IL4R(Qubit Pharmaceuticals) | Small molecule drug | Other Diseases | IL-4Rα modulators | Qubit Pharmaceuticals SAS | Qubit Pharmaceuticals SAS | Preclinical | - | - | - | - | - | - | - | - | - | IL4R(Qubit Pharmaceuticals) | - | - | detail > | |
| ZW-1528 | ZW-1528 | Bispecific antibody | Infectious Diseases Respiratory Diseases | IL-33 inhibitors IL-4Rα inhibitors | Zymeworks, Inc. | Zymeworks, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | ZW-1528 | - | - | detail > | |
| BET206-01 | BET206-01 | Nanobody | Immune System Diseases Infectious Diseases Congenital Disorders Otorhinolaryngologic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases | IL-4Rα inhibitors TSLP inhibitors | Bonentai (Shandong) Biomedical Technology Group Co., Ltd. | Bonentai (Shandong) Biomedical Technology Group Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | BET206-01 | - | - | detail > | |
| ZW1572 | ZW1572 | Bispecific antibody | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | IL-31 inhibitors IL-4Rα inhibitors | Zymeworks, Inc. | Zymeworks, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | ZW1572 | - | - | detail > | |
| IL-4-X | IL-4-X | Synthetic peptide | Skin and Musculoskeletal Diseases | IL-4Rα modulators | University of Warsaw | University of Warsaw | Preclinical | - | - | - | - | - | - | - | - | - | IL-4-X | - | - | detail > | |
| IL-4Rα inhibitor (Atomwise) | IL-4Rα inhibitor (Atomwise) | Small molecule drug | Immune System Diseases | IL-4Rα inhibitors | Atomwise, Inc. | Atomwise, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | IL-4Rα inhibitor (Atomwise) | - | - | detail > | |
| KROS-401 | KROS-401 | Synthetic peptide | Neoplasms Skin and Musculoskeletal Diseases | IL-13R inhibitors IL-4Rα inhibitors | Kairos Pharma Ltd. | Kairos Pharma Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | KROS-401 | - | - | detail > |
Total 96 data
1
2
3
4
5
6
...
9
10
